ROAD MAP: Getting a Cancer Study Done at Jefferson Sylvia O’Neill, MD Associate Director of Regulatory Affairs and Quality Assurance Clinical Trials Office.

Slides:



Advertisements
Similar presentations
The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.
Advertisements

Managing Compliance Related to Human Subjects Research Review Joseph Sherwin, Ph.D. Office of Regulatory Affairs University of Pennsylvania Fourth Annual.
What is a Data and Safety Monitoring Plan and how do I get one? Presented by Office of Human Research Protection.
Step by Step Guide for Regulations S HELLY B EZANSON K ELLY O FFICE OF G ENERAL C OUNSEL S EPTEMBER 5, 2012.
FDA Research: Clearance Requirements and Implications Steven L. Bradbard, Ph.D. Team Leader, Consumer Studies CFSAN/ORPSS.
Multi-Institutional Facilitated IRB Review Philip A. Cola, MA Vice President, Research and Technology University Hospitals Case Medical Center Third Annual.
Submission to Approval What happens to my protocol once I submit it to the HIC office.
CRC Protocol Documents Protocol Submissions Amendments Publications Study Closure.
 The National Cancer Institute (NCI) is:  The largest of the Institutes that constitute the National Institutes of Health  The largest sponsor of research.
Recently Issued OHRP Documents: Guidance on Subject Withdrawal and Draft Revised FWA Secretary’s Advisory Committee on Human Research Protections October.
IRB Basics Helen Panageas New York University School of Medicine Institutional Review Board Portion of slides courtesy of Suzanne M. Smith, University.
Brookhaven Science Associates U.S. Department of Energy 1 Brookhaven National Laboratory Protocol Compliance Monitoring Darcy Mallon May 7, 2009.
Integrated Online Research Compliance System (iORC)
Unlocking the Mystery of General Information Reporting Research Compliance Administration Training Presentation Wednesday, June 6, 2007 Presenter:Heather.
NCI Clinical Trials Reporting Program CTRP User Meeting May 2, 2012 Gene Kraus CTRP Program Director.
Continuing Review VA Requirements Kevin L. Nellis, M.S., M.T. (A.S.C.P.) Program Analyst Program for Research Integrity Development and Education (PRIDE)
Working with Quorum Allina Health Megan Simpson, CIP Senior Study Manager Allina Account Manager.
Response to FDA Audit 483 MX-4501N : Nine Category 483 Citations Meetings Minutes: Votes for, against, abstention and reason not recorded;
R ESEARCH P ROTECTIONS R EVIEW & F UNDING Nancy Stalnaker, Director & Donna Silver, Assistant Director UVM Research Protections Office 6/3/2013UVM Research.
Ethics and Regulatory Approvals Alison Robertson CMDHB Research Officer.
 Understanding the IRB Process University of Tennessee Health Science Center Institutional Review Board.
DCB New Grantee Workshop: Post-Award Administration of Grants Brett Hodgkins Team Leader National Cancer Institute Office of Grants Administration.
Michelle Groy Johnson Quality Improvement Officer Research Integrity Office Tough Love: Understanding the Purpose and Processes of Quality Assurance.
Deciphering the Continuing Review Form Research Compliance Administration Training Presentation Wednesday, August 15, 2007 Presenter:Heather Kemp, MBA.
East Tennessee State University. Full Accreditation Association for the Accreditation of Human Research Protection Programs (AAHRPP)
H I P A A T R A I N I N G Self Directed Module 7 Research Disclosures For Data Custodians START Click to begin…
The Institutional Review Board: A Community College Toolkit Dr. Geri J Anderson.
How to Successfully Apply to the IRB Richard Gordin, IRB Chair True Rubal, Administrator / Director For the Protection of Human Participants in Research.
SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.
DCB New Grantee Workshop: Post-Award Administration of Grants Brett Hodgkins Team Leader National Cancer Institute Office of Grants Administration.
Western Oregon University INSTITUTIONAL REVIEW BOARD.
Renewals A HOW-TO. Objectives 1.Why are renewals necessary? 2.What projects require a renewal? 3.How do I find the form? 4.How do I fill out the form?
LETTER OF INTENT FOR INDUSTRY SPONSORED RESEARCH Signe Denmark, SCTR Research Opportunities & Collaborations Ryan Mulligan, SCTR Grants & Contracts Navigator.
Continuing Review Presented by: Karen Jeans, PhD, CCRN, CIP Program Analyst, COACH.
CTRP User Call May 7, 2014 Gene Kraus CTRP Program Director.
Fully accredited since 2006 Tom Conquergood, CIP Working with Quorum October 13, 2015 Thomas Jefferson University.
Conducting Research at Lincoln IRB/HRPP Policies, Procedures & Good Clinical Practices B Kanna MD, MPH, FACP Associate Program Director of Internal Medicine.
1 Mission Impossible: Understanding the Pre-Award Grant Process Monique Foxx, MHSA Manager, Office of Sponsored Programs Stephanie Bair, MS Grants Management.
Sponsor Visits and Monitoring
The TJU Human Research Protection Program (HRPP): Part I – Which Entities/Offices are Involved ? J. Bruce Smith, MD, CIP.
Non-compliance with Human Subjects Research Regulations J. Bruce Smith, MD, CIP November 2014 Continuing Education for IRB Members.
ACRIN CV Committee ACRIN PDRC ACRIN PA 4008 Protocol and Regulatory Requirements Patricia Atkinson, Quality Control Monitor.
ROAD MAP: Getting a Cancer Study Done at Jefferson Sylvia O’Neill, MD Associate Director of Regulatory Affairs and Quality Assurance Clinical Trials Office.
Institutional Review Board (IRB) 101 Oleg Kisselev, Administrative IRB Chair *This presentation was prepared/presented.
May 5, 2016 Working With CTO Contracting: How Do I Get My Clinical Trial Contract Negotiated & Why Isn’t It Signed Yet? Jaci Brown, Manager, CTO-Contracting.
Lifespan 1 Submission Process to the IRB part 2 Revisions to Protocol.
ROAD MAP: Getting a Cancer Study Done at Jefferson Meghan Wakefield,RN,CCRP Senior Director of Clinical Trials Office Clinical Research Organization.
Department of Defense (DoD) Funded Human Subjects Research J. Bruce Smith, MD.
© 2016 University at Buffalo Click Training IRB Module University at Buffalo Office of the Vice President for Research and Economic Development Electronic.
© 2016 University at Buffalo Click Training Safety Module University at Buffalo Office of the Vice President for Research and Economic Development Electronic.
IRB BASICS BETTY WILSON, MS, CIP. CONCEPTS SUBMISSION APPROVAL RECRUITING WORKING WITH PRINCIPAL INVESTIGATOR (PI) /SPONSOR POLICIES DEVIATIONS RECORD.
An Administrator’s Guide to Grant Management Presented by WCRI Research Administration and WCH Finance Department Grant Management 201 new thinking.
Rare Diseases Clinical Research Network Data Management and Coordinating Center (RDCRN DMCC) Rosalie Holland LDN Investigator Meeting at WORLDSymposium.
Sponsor Visits and Monitoring Barbara Gallagher, RN Clinical Research Nurse Jefferson Clinical Research Institute.
Introduction Review and proper registration of Human Gene Transfer protocols is very complex. A protocol goes through rigorous review by multiple Committees.
Conditional IRB Approval
Introduction to the Human Research Protections Office (HRPO)
COCE Institutional Review Board Academic Spotlight
Recent Evolution of New Drug Review and Approval System in Korea
University of Central Florida Office of Research & Commercialization
Submission Process to the IRB part 1 New and Continuing Reviews
FDA’s IDE Decisions and Communications
What is a Data and Safety Monitoring Plan and how do I get one?
Reportable Events & Other IRB Updates February 2017
Oncology Clinical Trials
Oncology Clinical Trials
Claire McKinley, PMP, CCRP
Clinical Trial Development: NRG Processes and NCI Requirements
Clinical Trial Development: NRG Processes and NCI Requirements
Presentation transcript:

ROAD MAP: Getting a Cancer Study Done at Jefferson Sylvia O’Neill, MD Associate Director of Regulatory Affairs and Quality Assurance Clinical Trials Office

NCI Guidelines AKA: the CORE Grant As an NCI Designated Cancer Center we are mandated to follow the current NCI guidelines. All cancer trials enrollment need to be registered All status changes are done through Alex Lebrun

Org chart

The submission process MDG PRC IRB PRC and IRB Simultaneous Amendments New trial

Multi-disciplinary Groups GI Aero-Digestive Hematologic Women’s Cancer GU Melanoma and Cutaneous Malignacies Solid Tumors

Protocol Review Committee (fka: CCRRC) comprises investigators broadly representing basic and clinical sciences that: Reviews scientific integrity of cancer clinical trials Meetings occur the second and fourth Monday of the month Deadlines are two weeks prior to the meeting Reviewers are not confidential and there is open communication Cancer trials are not reviewed by IRB without written PRC approval IRB copied on correspondence from PRC to PIs regarding trial closure for compliance or accrual Assures protocol compliance by monitoring accrual

Protocol Review Committee Approval Format: Approved Approved with administrative changes Changes must be made but do not need to come back to PRC Approval with the following recommendations --- optional The PRC will sign off on protocols with no further review and the IRB will be made aware of the recommendations. Changes are not required and do not need to come back to PRC Conditional approval with mandatory stipulation changes The PRC final approval letter will not be sent to the PI until the issues raised here are completed satisfactorily Changes come back to the Administrative Chair for verification of change but do not go back to the full board for approval Disapproved- revisions needed Disapproved

PRC Amendment review When must an amendment get PRC approval? The amendment changes at least one of the following: a. Inclusion/exclusion criteria b. Objectives c. Statistics d. Subject population How do amendments get submitted to PRC? Send an to: and attach the following documents: 1. MCSF with tracked changes 2. Summary of changes 3. Tracked

Closure Policy Per NCI Guidelines we must close trials that are not or have low accruals. Zero accrual at 6 months after activation Have less than 15% after 6 months of activation Have less than 30 % after one year of activation We are allowed to suspend the clock on a trial, please notify us at

Data Safety Monitoring Committee Policy established in collaboration with the NCI in 2011 Meets quarterly Currently oversees 42 IIT clinical trials The DSMC coordinator assigns a Medical Monitor – recommends continuation, suspension, or termination May call for an adhoc meeting to discuss action plans Assign a category of risk to every IIT

In a nutshell….. Call our Clinical Trials Office (fka CRMO) the PRC at :